MacroGenics, Inc. (NASDAQ:MGNX) Given Consensus Rating of “Hold” by Analysts

MacroGenics, Inc. (NASDAQ:MGNX) has earned an average recommendation of “Hold” from the eleven analysts that are covering the company, MarketBeat.com reports. Eight analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $7.63.

Several equities research analysts have issued reports on MGNX shares. StockNews.com raised MacroGenics from a “sell” rating to a “buy” rating in a report on Sunday, November 10th. HC Wainwright restated a “neutral” rating and set a $4.00 target price on shares of MacroGenics in a research note on Wednesday, November 6th. Evercore ISI upgraded shares of MacroGenics to a “strong-buy” rating in a research note on Monday, September 16th. Finally, JMP Securities downgraded shares of MacroGenics from an “outperform” rating to a “market perform” rating in a research report on Thursday, November 7th.

MacroGenics Stock Down 1.8 %

Shares of NASDAQ MGNX opened at $3.35 on Thursday. The business’s 50 day moving average price is $3.51 and its two-hundred day moving average price is $3.75. The company has a market cap of $210.26 million, a PE ratio of -2.12 and a beta of 2.04. MacroGenics has a twelve month low of $2.95 and a twelve month high of $21.88.

Institutional Investors Weigh In On MacroGenics

A number of large investors have recently added to or reduced their stakes in MGNX. Barclays PLC lifted its position in shares of MacroGenics by 97.1% during the 3rd quarter. Barclays PLC now owns 98,753 shares of the biopharmaceutical company’s stock valued at $325,000 after acquiring an additional 48,639 shares during the period. XTX Topco Ltd acquired a new position in MacroGenics in the third quarter valued at about $37,000. Wellington Management Group LLP lifted its position in MacroGenics by 15.7% during the third quarter. Wellington Management Group LLP now owns 307,140 shares of the biopharmaceutical company’s stock worth $1,010,000 after purchasing an additional 41,733 shares during the period. Stifel Financial Corp grew its stake in MacroGenics by 19.7% during the third quarter. Stifel Financial Corp now owns 39,888 shares of the biopharmaceutical company’s stock worth $131,000 after buying an additional 6,578 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. increased its holdings in MacroGenics by 35.2% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 566,328 shares of the biopharmaceutical company’s stock valued at $1,863,000 after buying an additional 147,438 shares during the period. Institutional investors and hedge funds own 96.89% of the company’s stock.

MacroGenics Company Profile

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.